All PlansAdministrativeMedium impact
Voluntary nationwide recall: Clonazepam (Endo – November)
UPMC Health Plan·Psychiatry, Neurology, Pharmacy·Pharmacy
We identified it
Aug 7, 2026
Summary
Endo USA Inc. has issued a voluntary nationwide recall of certain lots of Clonazepam Orally Disintegrating Tablets due to incorrect product strength labeling on cartons (though blister strips show correct strength). Patients who received affected lots should stop using the medication and return it to their pharmacy. This is an expansion of a previous recall. As of Nov. 18, no adverse events have been reported.
Action Required
Immediately: Billing and clinical staff should alert patients currently prescribed Clonazepam ODT to contact their pharmacy or prescribing provider to verify whether their medication lot is affected by this recall. Post recall notice in patient communication systems and pharmacy areas. Providers should review active Clonazepam prescriptions and contact patients as appropriate. No billing system changes are required, but communication protocols should be activated to notify potentially affected patients. Coordinate with pharmacy to ensure recalled lots are not dispensed.